Maximiliaan L. Notenboom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maximiliaan L. Notenboom has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Johanna Josepha Maria Takkenberg
Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands
14 shared publications - Kevin M. Veen
Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands
9 shared publications - Jolien W. Roos-Hesselink
Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus MC, Rotterdam, The Netherlands
6 shared publications - Ad J. J. C. Bogers
Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands
5 shared publications - Guillaume S. C. Geuzebroek
Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
4 shared publications - Jonathan Richard Gregory Etnel
Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands
4 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (4)
Sex-Related Differences in Histopathology and Hormonal Associations in Ascending Aortic Aneurysms
Background and Aims: Sex-related differences in ascending aorta aneurysm (AscAA) pathology and the underlying mechanisms remain incompletely understood. In this study, sex-specific patterns of aortic media degeneration (MD) in idiopathic AscAA were investigated. Methods: Aortic tissue and blood samples were obtained from 32 patients undergoing elective AscAA resection (mean age 65.6 years, 25% women). Two donor aortas served as healthy controls. Tissues were evaluated using a modified consensus scoring system assessing elastin integrity, mucoid extracellular matrix accumulation (MEMA), smooth muscle cell organization, and collagen remodeling. Immunohistochemistry was used to quantify extracellular matrix and remodeling markers. Outcome parameters included aortic diameter, immunohistochemical profiling, MD scores, and sex hormone profiling. Results: Absolute ascending aortic diameters did not differ between sexes. Women exhibited significantly more advanced and diffuse MD across all sampled locations, with higher total MD scores before and after adjustment for aortic size. This was attributed to increased elastin degradation, MEMA, and elevated local MMP2 expression, consistent with a degradative remodeling profile. In contrast, men displayed a more focal and inflammatory phenotype, characterized by increased MMP9, cKIT, and CD68 expression, and relatively thicker media. Circulating hormone levels were reduced in both sexes but were not directly associated with MD severity. However, female-specific decreases in DHEA and male-specific decreases in testosterone, AMH, and androstenedione were observed. Conclusions: This study reveals pronounced sex-specific differences in AscAA wall degeneration. Women demonstrate a structurally more vulnerable aortic wall at comparable dilatation, fueling discussion for revision of female treatment plans.
- 26 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (4)
Open AccessSex-Related Differences in Histopathology and Hormonal Associations in Ascending Aortic Aneurysms
Background and Aims: Sex-related differences in ascending aorta aneurysm (AscAA) pathology and the underlying mechanisms remain incompletely understood. In this study, sex-specific patterns of aortic media degeneration (MD) in idiopathic AscAA were investigated. Methods: Aortic tissue and blood samples were obtained from 32 patients undergoing elective AscAA resection (mean age 65.6 years, 25% women). Two donor aortas served as healthy controls. Tissues were evaluated using a modified consensus scoring system assessing elastin integrity, mucoid extracellular matrix accumulation (MEMA), smooth muscle cell organization, and collagen remodeling. Immunohistochemistry was used to quantify extracellular matrix and remodeling markers. Outcome parameters included aortic diameter, immunohistochemical profiling, MD scores, and sex hormone profiling. Results: Absolute ascending aortic diameters did not differ between sexes. Women exhibited significantly more advanced and diffuse MD across all sampled locations, with higher total MD scores before and after adjustment for aortic size. This was attributed to increased elastin degradation, MEMA, and elevated local MMP2 expression, consistent with a degradative remodeling profile. In contrast, men displayed a more focal and inflammatory phenotype, characterized by increased MMP9, cKIT, and CD68 expression, and relatively thicker media. Circulating hormone levels were reduced in both sexes but were not directly associated with MD severity. However, female-specific decreases in DHEA and male-specific decreases in testosterone, AMH, and androstenedione were observed. Conclusions: This study reveals pronounced sex-specific differences in AscAA wall degeneration. Women demonstrate a structurally more vulnerable aortic wall at comparable dilatation, fueling discussion for revision of female treatment plans.
- Open Access
- 13 January 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (2)
The GERAADA Risk Score for Early Mortality After Surgery for Acute Type A Aortic Dissection: An External Validation in the Dutch Setting
Objectives: Acute type A aortic dissection (ATAAD) carries high mortality, with emergency surgery being the cornerstone of treatment. The German Registry for Acute Type A Aortic Dissection (GERAADA)-score is advocated in guidelines to predict 30-day mortality after ATAAD surgery. This study investigates its performance in a Dutch cohort, with an emphasis on malperfusion definitions, age groups, and sex. Methods: Adults undergoing emergency surgery for ATAAD at 5 Dutch centres (2007-2024) were included in a multicentre database. External validation of the GERAADA-score was performed with these data, using discrimination (area under the curve [AUC]) and calibration (Brier score, Hosmer-Lemeshow test, and calibration plots). A logistic regression with GERAADA variables was fitted on the study population, and assumptions were checked. Subgroup analyses were conducted based on sex, age groups, and malperfusion definitions (including imaging and clinical definitions). Results: A total of 1,146 patients underwent emergency surgery for ATAAD. Observed early mortality was 16.9% (n = 194). Of 1,130 patients included in the external validation cohort, 92.2% had low-intermediate risk (GERAADA-score ≤ 30%). The GERAADA-score showed moderate discrimination (AUC = 0.649, 95% confidence interval = 0.604-0.694), with a higher AUC for younger patients (50-59 years). The malperfusion definition including ischaemia confirmed by imaging showed the best discriminative power. Calibration was good (Hosmer-Lemeshow, P = .754, Brier score = 0.131). Logistic regression identified age, catecholamine use, ventilation support, and coronary and peripheral malperfusion as independent risk factors for 30-day mortality, with signs of multicollinearity between preoperative catecholamine use and resuscitation. Conclusions: In the Dutch setting, the GERAADA-score demonstrated moderate discriminative power and good calibration across relevant subgroups. Adaptations of the GERAADA-score, including conducting a haemodynamic instability variable, may be considered to avoid redundant predictions and boost reproducibility.
- 13 January 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (2)
Open AccessThe GERAADA Risk Score for Early Mortality After Surgery for Acute Type A Aortic Dissection: An External Validation in the Dutch Setting
Objectives: Acute type A aortic dissection (ATAAD) carries high mortality, with emergency surgery being the cornerstone of treatment. The German Registry for Acute Type A Aortic Dissection (GERAADA)-score is advocated in guidelines to predict 30-day mortality after ATAAD surgery. This study investigates its performance in a Dutch cohort, with an emphasis on malperfusion definitions, age groups, and sex. Methods: Adults undergoing emergency surgery for ATAAD at 5 Dutch centres (2007-2024) were included in a multicentre database. External validation of the GERAADA-score was performed with these data, using discrimination (area under the curve [AUC]) and calibration (Brier score, Hosmer-Lemeshow test, and calibration plots). A logistic regression with GERAADA variables was fitted on the study population, and assumptions were checked. Subgroup analyses were conducted based on sex, age groups, and malperfusion definitions (including imaging and clinical definitions). Results: A total of 1,146 patients underwent emergency surgery for ATAAD. Observed early mortality was 16.9% (n = 194). Of 1,130 patients included in the external validation cohort, 92.2% had low-intermediate risk (GERAADA-score ≤ 30%). The GERAADA-score showed moderate discrimination (AUC = 0.649, 95% confidence interval = 0.604-0.694), with a higher AUC for younger patients (50-59 years). The malperfusion definition including ischaemia confirmed by imaging showed the best discriminative power. Calibration was good (Hosmer-Lemeshow, P = .754, Brier score = 0.131). Logistic regression identified age, catecholamine use, ventilation support, and coronary and peripheral malperfusion as independent risk factors for 30-day mortality, with signs of multicollinearity between preoperative catecholamine use and resuscitation. Conclusions: In the Dutch setting, the GERAADA-score demonstrated moderate discriminative power and good calibration across relevant subgroups. Adaptations of the GERAADA-score, including conducting a haemodynamic instability variable, may be considered to avoid redundant predictions and boost reproducibility.
- Open Access
- 9 October 2025
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 22, 100626
Clinical course of severe congenital aortic valve stenosis in children
- 9 October 2025
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 22, 100626
Open AccessClinical course of severe congenital aortic valve stenosis in children
- Open Access
- 1 October 2025
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 2 (3-4) , 314-316
Global Momentum for the Ross Procedure: Now is the Time
- 1 October 2025
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 2 (3-4) , 314-316
Open AccessGlobal Momentum for the Ross Procedure: Now is the Time
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (2) , e009993
How to Put Survival After Cardiothoracic Interventions in the General Population Context: A Case-Based Practical Guideline to Calculate Cumulative Matched-General-Population Survival
BACKGROUND: Observed patient survival after cardiothoracic interventions should ideally be placed in the context of matched-general-population survival. This study outlines several methodologies of matching general population mortality to the study sample, subsequently calculating cumulative matched-general-population survival, highlighting their respective advantages, disadvantages, and limitations. METHODS: A multicenter data set containing survival data after the Ross procedure was used for methodological illustration. General population mortality was extracted from country-specific life tables in the Human Mortality Database. The matched-general-population mortality, also known as background mortality, was obtained by matching general population mortality to the study sample using different matching strategies, iteratively considering median/individual age and median/individual calendar year, besides country and sex. The corresponding cumulative matched-general-population survival was calculated subsequently. Sensitivity analyses were performed to assess the impact of varying patient ages on survival estimates by adding and subtracting 15 years from individual patients. A web-based Shiny Application (App) was developed to easily calculate cumulative matched-general-population survival. RESULTS: In total, 1431 hospital survivors from the Ross procedure from 5 countries (25.7% female; median age, 48.5 [interquartile range, 42.7–54.0] years) were included. Fifteen-year survival was 88.3% (95% CI, 85.3–90.6). Cumulative matched-general-population 15-year survival varied from 87.7% to 89.8% using the 3 methods of different complexities. For 15-year-older patients, the cumulative matched-general-population 15-year survival was 67.4%, 59.8%, and 63.2%, respectively, using the simplest to the most comprehensive matching methods; for 15-year-younger patients, it was 96.9%, 96.1%, and 96.7%, respectively. CONCLUSIONS: Different methodologies to match general population mortality to observed patient mortality yield variable estimates of cumulative matched-general-population survival, especially in older patients. The cumulative matched-general-population survival should ideally be calculated by considering country, sex, individual patient age, and calendar year (both updated annually). This method can be easily implemented using the web-based Shiny App enclosed in this article.
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (2) , e009993
How to Put Survival After Cardiothoracic Interventions in the General Population Context: A Case-Based Practical Guideline to Calculate Cumulative Matched-General-Population Survival
BACKGROUND: Observed patient survival after cardiothoracic interventions should ideally be placed in the context of matched-general-population survival. This study outlines several methodologies of matching general population mortality to the study sample, subsequently calculating cumulative matched-general-population survival, highlighting their respective advantages, disadvantages, and limitations. METHODS: A multicenter data set containing survival data after the Ross procedure was used for methodological illustration. General population mortality was extracted from country-specific life tables in the Human Mortality Database. The matched-general-population mortality, also known as background mortality, was obtained by matching general population mortality to the study sample using different matching strategies, iteratively considering median/individual age and median/individual calendar year, besides country and sex. The corresponding cumulative matched-general-population survival was calculated subsequently. Sensitivity analyses were performed to assess the impact of varying patient ages on survival estimates by adding and subtracting 15 years from individual patients. A web-based Shiny Application (App) was developed to easily calculate cumulative matched-general-population survival. RESULTS: In total, 1431 hospital survivors from the Ross procedure from 5 countries (25.7% female; median age, 48.5 [interquartile range, 42.7–54.0] years) were included. Fifteen-year survival was 88.3% (95% CI, 85.3–90.6). Cumulative matched-general-population 15-year survival varied from 87.7% to 89.8% using the 3 methods of different complexities. For 15-year-older patients, the cumulative matched-general-population 15-year survival was 67.4%, 59.8%, and 63.2%, respectively, using the simplest to the most comprehensive matching methods; for 15-year-younger patients, it was 96.9%, 96.1%, and 96.7%, respectively. CONCLUSIONS: Different methodologies to match general population mortality to observed patient mortality yield variable estimates of cumulative matched-general-population survival, especially in older patients. The cumulative matched-general-population survival should ideally be calculated by considering country, sex, individual patient age, and calendar year (both updated annually). This method can be easily implemented using the web-based Shiny App enclosed in this article.
- Open Access
- 1 October 2024
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 1 (1)
The Ross Procedure in Adults
The ideal aortic valve substitute in adults remains a matter of intense debate. With the advent of transcatheter procedures, the concept of lifetime management of aortic valve disease has gained further momentum. The Ross procedure represents the only replacement option that ensures long-term viability of the aortic valve substitute. This provides unique biological and hemodynamic benefits, which have translated into clinically relevant benefits for patients. In recent years, better understanding of the technical nuances of the operation and recognition of the importance of surgical expertise have further improved outcomes. The current review provides a comprehensive examination of the current role of the Ross procedure in adults in contemporary practice, including indications, technical elements and special considerations.
- 1 October 2024
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 1 (1)
Open AccessThe Ross Procedure in Adults
The ideal aortic valve substitute in adults remains a matter of intense debate. With the advent of transcatheter procedures, the concept of lifetime management of aortic valve disease has gained further momentum. The Ross procedure represents the only replacement option that ensures long-term viability of the aortic valve substitute. This provides unique biological and hemodynamic benefits, which have translated into clinically relevant benefits for patients. In recent years, better understanding of the technical nuances of the operation and recognition of the importance of surgical expertise have further improved outcomes. The current review provides a comprehensive examination of the current role of the Ross procedure in adults in contemporary practice, including indications, technical elements and special considerations.
- Open Access
- 26 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (6) , 551-564
Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study
To explore male–female differences in aneurysm growth and clinical outcomes in a two-centre retrospective Dutch cohort study of adult patients with ascending aortic aneurysm (AscAA). Adult patients in whom imaging of an AscAA (root and/or ascending: ≥40 mm) was performed between 2007 and 2022 were included. Aneurysm growth was analysed using repeated measurements at the sinuses of Valsalva (SoV) and tubular ascending aorta. Male–female differences were explored in presentation, aneurysm characteristics, treatment strategy, survival, and clinical outcomes. One thousand eight hundred and fifty-eight patients were included (31.6% female). Median age at diagnosis was 65.4 years (interquartile range: 53.4–71.7) for females and 59.0 years (interquartile range: 49.3–68.0) for males (P < .001). At diagnosis, females more often had tubular ascending aortic involvement (75.5% vs. 70.2%; P = .030) while males more often had SoV involvement (42.8% vs. 21.6%; P < .001). Maximum absolute aortic diameter, at any location, at diagnosis did not differ between females (45.0 mm) and males (46.5 mm; P = .388). In females, tubular ascending growth was faster (P < .001), whereas in males, SoV growth was faster (P = .005), corrected for covariates. Unadjusted 10-year survival was 72.5% [95% confidence interval (CI) 67.8%–77.6%] for females and 78.3% (95% CI 75.3%–81.3%) for males (P = .010). Twenty-three type A dissections occurred, with an incidence rate of 8.2/1000 patient-years (95% CI 4.4–14.1) in females and 2.4/1000 patient-years (95% CI 1.2–4.5) in males [incidence rate ratio females/males: 3.4 (95% CI 1.5–8.0; P = .004)]. In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development. Comparative analysis of long-term clinical outcome and segment-specific aortic growth in males and females diagnosed with an aortic root and/or ascending aortic aneurysm. AscAA, ascending aortic aneurysm.
- 26 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (6) , 551-564
Open AccessSex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study
To explore male–female differences in aneurysm growth and clinical outcomes in a two-centre retrospective Dutch cohort study of adult patients with ascending aortic aneurysm (AscAA). Adult patients in whom imaging of an AscAA (root and/or ascending: ≥40 mm) was performed between 2007 and 2022 were included. Aneurysm growth was analysed using repeated measurements at the sinuses of Valsalva (SoV) and tubular ascending aorta. Male–female differences were explored in presentation, aneurysm characteristics, treatment strategy, survival, and clinical outcomes. One thousand eight hundred and fifty-eight patients were included (31.6% female). Median age at diagnosis was 65.4 years (interquartile range: 53.4–71.7) for females and 59.0 years (interquartile range: 49.3–68.0) for males (P < .001). At diagnosis, females more often had tubular ascending aortic involvement (75.5% vs. 70.2%; P = .030) while males more often had SoV involvement (42.8% vs. 21.6%; P < .001). Maximum absolute aortic diameter, at any location, at diagnosis did not differ between females (45.0 mm) and males (46.5 mm; P = .388). In females, tubular ascending growth was faster (P < .001), whereas in males, SoV growth was faster (P = .005), corrected for covariates. Unadjusted 10-year survival was 72.5% [95% confidence interval (CI) 67.8%–77.6%] for females and 78.3% (95% CI 75.3%–81.3%) for males (P = .010). Twenty-three type A dissections occurred, with an incidence rate of 8.2/1000 patient-years (95% CI 4.4–14.1) in females and 2.4/1000 patient-years (95% CI 1.2–4.5) in males [incidence rate ratio females/males: 3.4 (95% CI 1.5–8.0; P = .004)]. In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development. Comparative analysis of long-term clinical outcome and segment-specific aortic growth in males and females diagnosed with an aortic root and/or ascending aortic aneurysm. AscAA, ascending aortic aneurysm.
- 1 March 2024
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (3)
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve disease
Summary: Treatment decisions in healthcare often carry lifelong consequences that can be challenging to foresee. As such, tools that visualize and estimate outcome after different lifetime treatment strategies are lacking and urgently needed to support clinical decision-making in the setting of rapidly evolving healthcare systems, with increasingly numerous potential treatments. In this regard, microsimulation models may prove to be valuable additions to current risk-prediction models. Notable advantages of microsimulation encompass input from multiple data sources, the ability to move beyond time-to-first-event analysis, accounting for multiple types of events and generating projections of lifelong outcomes. This review aims to clarify the concept of microsimulation, also known as individualized state-transition models, and help clinicians better understand its potential in clinical decision-making. A practical example of a patient with heart valve disease is used to illustrate key components of microsimulation models, such as health states, transition probabilities, input parameters (e.g. evidence-based risks of events) and various aspects of mortality. Finally, this review focuses on future efforts needed in microsimulation to allow for increasing patient-tailoring of the models by extending the general structure with patient-specific prediction models and translating them to meaningful, user-friendly tools that may be used by both clinician and patient to support clinical decision-making.
- 1 March 2024
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (3)
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve disease
Summary: Treatment decisions in healthcare often carry lifelong consequences that can be challenging to foresee. As such, tools that visualize and estimate outcome after different lifetime treatment strategies are lacking and urgently needed to support clinical decision-making in the setting of rapidly evolving healthcare systems, with increasingly numerous potential treatments. In this regard, microsimulation models may prove to be valuable additions to current risk-prediction models. Notable advantages of microsimulation encompass input from multiple data sources, the ability to move beyond time-to-first-event analysis, accounting for multiple types of events and generating projections of lifelong outcomes. This review aims to clarify the concept of microsimulation, also known as individualized state-transition models, and help clinicians better understand its potential in clinical decision-making. A practical example of a patient with heart valve disease is used to illustrate key components of microsimulation models, such as health states, transition probabilities, input parameters (e.g. evidence-based risks of events) and various aspects of mortality. Finally, this review focuses on future efforts needed in microsimulation to allow for increasing patient-tailoring of the models by extending the general structure with patient-specific prediction models and translating them to meaningful, user-friendly tools that may be used by both clinician and patient to support clinical decision-making.
- Open Access
- 1 February 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (2) , 49
Aortic Valve Embryology, Mechanobiology, and Second Messenger Pathways: Implications for Clinical Practice
During the Renaissance, Leonardo Da Vinci was the first person to successfully detail the anatomy of the aortic root and its adjacent structures. Ever since, novel insights into morphology, function, and their interplay have accumulated, resulting in advanced knowledge on the complex functional characteristics of the aortic valve (AV) and root. This has shifted our vision from the AV as being a static structure towards that of a dynamic interconnected apparatus within the aortic root as a functional unit, exhibiting a complex interplay with adjacent structures via both humoral and mechanical stimuli. This paradigm shift has stimulated surgical treatment strategies of valvular disease that seek to recapitulate healthy AV function, whereby AV disease can no longer be seen as an isolated morphological pathology which needs to be replaced. As prostheses still cannot reproduce the complexity of human nature, treatment of diseased AVs, whether stenotic or insufficient, has tremendously evolved, with a similar shift towards treatments options that are more hemodynamically centered, such as the Ross procedure and valve-conserving surgery. Native AV and root components allow for an efficient Venturi effect over the valve to allow for optimal opening during the cardiac cycle, while also alleviating the left ventricle. Next to that, several receptors are present on native AV leaflets, enabling messenger pathways based on their interaction with blood and other shear-stress-related stimuli. Many of these physiological and hemodynamical processes are under-acknowledged but may hold important clues for innovative treatment strategies, or as potential novel targets for therapeutic agents that halt or reverse the process of valve degeneration. A structured overview of these pathways and their implications for cardiothoracic surgeons and cardiologists is lacking. As such, we provide an overview on embryology, hemodynamics, and messenger pathways of the healthy and diseased AV and its implications for clinical practice, by relating this knowledge to current treatment alternatives and clinical decision making.
- 1 February 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (2) , 49
Open AccessAortic Valve Embryology, Mechanobiology, and Second Messenger Pathways: Implications for Clinical Practice
During the Renaissance, Leonardo Da Vinci was the first person to successfully detail the anatomy of the aortic root and its adjacent structures. Ever since, novel insights into morphology, function, and their interplay have accumulated, resulting in advanced knowledge on the complex functional characteristics of the aortic valve (AV) and root. This has shifted our vision from the AV as being a static structure towards that of a dynamic interconnected apparatus within the aortic root as a functional unit, exhibiting a complex interplay with adjacent structures via both humoral and mechanical stimuli. This paradigm shift has stimulated surgical treatment strategies of valvular disease that seek to recapitulate healthy AV function, whereby AV disease can no longer be seen as an isolated morphological pathology which needs to be replaced. As prostheses still cannot reproduce the complexity of human nature, treatment of diseased AVs, whether stenotic or insufficient, has tremendously evolved, with a similar shift towards treatments options that are more hemodynamically centered, such as the Ross procedure and valve-conserving surgery. Native AV and root components allow for an efficient Venturi effect over the valve to allow for optimal opening during the cardiac cycle, while also alleviating the left ventricle. Next to that, several receptors are present on native AV leaflets, enabling messenger pathways based on their interaction with blood and other shear-stress-related stimuli. Many of these physiological and hemodynamical processes are under-acknowledged but may hold important clues for innovative treatment strategies, or as potential novel targets for therapeutic agents that halt or reverse the process of valve degeneration. A structured overview of these pathways and their implications for cardiothoracic surgeons and cardiologists is lacking. As such, we provide an overview on embryology, hemodynamics, and messenger pathways of the healthy and diseased AV and its implications for clinical practice, by relating this knowledge to current treatment alternatives and clinical decision making.